Expertise in
25
conditions

Stephanie E. Combs

Ismaninger Str. 22, 
Munich, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
25
conditions
Ismaninger Str. 22, 
Munich, BY, DE 

Overview

Stephanie Combs practices in Munich, Germany. Ms. Combs is highly rated in 25 conditions, according to our data. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, Mastectomy, and Prostatectomy.

Her clinical research consists of co-authoring 679 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Other
Study Phase: Not Applicable
Observational Study on Biomarkers in Head and Neck Cancer
Observational Study on Biomarkers in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma
Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma
Enrollment Status: Completed
Publish Date: April 03, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial
Enrollment Status: Withdrawn
Publish Date: May 17, 2018
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial
Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial
Enrollment Status: Completed
Publish Date: May 17, 2018
Intervention Type: Radiation
Study Phase: Not Applicable
View 7 Less Clinical Trials

679 Total Publications

What is the future of nanoparticles as a clinical theranostic tool for glioblastoma?
What is the future of nanoparticles as a clinical theranostic tool for glioblastoma?
Journal: Expert review of molecular diagnostics
Published: April 04, 2026

Frequently Asked Questions about Stephanie E. Combs

Is Stephanie E. Combs a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Stephanie E. Combs is classified as an Elite expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephanie E. Combs participate in research or clinical trials?

Yes. Stephanie E. Combs has published 679 articles and abstracts on conditions like Glioma. You can view a list of Stephanie E. Combs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Combs's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 52 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile